

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
May 14, 2014

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	James Boblin M.D.	Yes
3	Ward Brown, M.D.	Yes
4	Catherine Decker PharmD	Yes
5	Ronald Diamond, M.D.	Yes
6	Lawrence Fleming M.D.	Yes
7	Kevin Izard M.D.	Yes
8	Steve Maike RPh	Yes
9	William E. Raduege, M.D.	Yes
10	Pat Towers	Yes
11	Alicia Walker PharmD	Yes
12	Michael Witkovsky M.D.	Yes

MAY 2014 THERAPEUTIC DRUG CLASS

ANGIOTENSIN MODULATORS
ANGIOTENSIN MODULATOR COMBINATIONS
BETA BLOCKERS
CALCIUM CHANNEL BLOCKERS
LIPOTROPICS, OTHER
LIPOTROPICS, STATINS
PAH AGENTS, ORAL AND INHALED
ANTICOAGULANTS
PLATELET AGGREGATION INHIBITORS
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
HYPOGLYCEMICS, MEGLITINIDES
HYPOGLYCEMICS, OTHER
HYPOGLYCEMICS, SULFONYLUREAS
HYPOGLYCEMICS, TZD
ANTIEMETIC/ANTIVERTIGO AGENTS
PANCREATIC ENZYMES
PROTON PUMP INHIBITORS
ULCERATIVE COLITIS AGENTS
H. PYLORI TREATMENT
ANTIBIOTICS, GI
ANTIBIOTICS, INHALED
ANTIBIOTICS, VAGINAL
ANTIFUNGALS, ORAL
ANTIVIRALS, ORAL
CEPHALOSPORINS AND RELATED AGENTS
PENICILLINS
FLUOROQUINOLONES, ORAL
MACROLIDES/KETOLIDES
TETRACYCLINES
ACNE AGENTS, TOPICAL
ANTIBIOTICS, TOPICAL
ANTIFUNGALS, TOPICAL
ANTIPARASITICS, TOPICAL
ANTIVIRALS, TOPICAL
ANALGESICS, MISCELLANEOUS
ANALGESICS, NARCOTICS LONG
ANALGESICS, NARCOTICS SHORT
OPIATE DEPENDENCY
ANTIMIGRAINE AGENTS
SKELETAL MUSCLE RELAXANTS
BLADDER RELAXANT PREPARATIONS
BONE RESORPTION SUPPRESSION AND RELATED AGENTS
ERYTHROPOIESIS STIMULATING PROTEINS
GROWTH HORMONE
ANDROGENIC AGENTS
BPH TREATMENTS
PHOSPHATE BINDERS
HEPATITIS B AGENTS
HEPATITIS C AGENTS
HIV/AIDS
MULTIPLE SCLEROSIS AGENTS
IRRITABLE BOWEL SYNDROME

Recommendations Summary:

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
UNIRETIC (ORAL)	0.0%	OFF	No			
LISINOPRIL HCTZ (ORAL)	10.6%	ON	Yes-Generic			
ENALAPRIL HCTZ (ORAL)	0.4%	ON	Yes-Generic			
QUINAPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
CAPTOPRIL HCTZ (ORAL)	0.0%	ON	No-Generic			
FOSINOPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
MOEXIPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
BENAZEPRIL HCTZ (ORAL)	0.6%	ON	No-Generic			
CAPTOPRIL (ORAL)	0.5%	ON	Yes-Generic			
UNIVASC (ORAL)	0.0%	OFF	No			
LISINOPRIL (ORAL)	45.5%	ON	Yes-Generic			
BENAZEPRIL (ORAL)	3.2%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.4%	ON	Yes-Generic			
FOSINOPRIL (ORAL)	0.0%	OFF	Yes-Generic			
ENALAPRIL (ORAL)	6.1%	ON	Yes-Generic			
QUINAPRIL (ORAL)	0.0%	OFF	No-Generic			
TRANDOLAPRIL (ORAL)	0.0%	OFF	No-Generic			
MOEXIPRIL (ORAL)	0.0%	OFF	No-Generic			
PERINDOPRIL (ORAL)	0.0%	OFF	No-Generic			
EPANED (ORAL)	0.0%	NR	No			
EDARBI (ORAL)	0.0%	OFF	No			
MICARDIS (ORAL)	0.1%	OFF	No			
BENICAR (ORAL)	0.3%	OFF	No			
ATACAND (ORAL)	0.1%	OFF	No			
DIOVAN (ORAL)	5.3%	ON	Yes			
LOSARTAN (ORAL)	18.7%	ON	Yes-Generic			
IRBESARTAN (ORAL)	0.2%	OFF	No-Generic			
TEVETEN (ORAL)	0.0%	OFF	No			
EPROSARTAN (ORAL)	0.0%	OFF	No-Generic			
CANDESARTAN (AG) (ORAL)	0.0%	NR	No-Generic			
TELMISARTAN (AG) (ORAL)	0.0%	NR	No-Generic			
CANDESARTAN (ORAL)	0.0%	NR	No-Generic			
TELMISARTAN (ORAL)	0.0%	NR	No-Generic			
EDARBYCLOR (ORAL)	0.0%	OFF	No			
MICARDIS HCT (ORAL)	0.1%	OFF	No			
BENICAR HCT (ORAL)	0.2%	OFF	No			
IRBESARTAN HCTZ (ORAL)	0.0%	OFF	No-Generic			
LOSARTAN HCTZ (ORAL)	5.7%	ON	Yes-Generic			
DIOVAN HCT (ORAL)	1.8%	ON	Yes			
TEVETEN HCT (ORAL)	0.0%	OFF	No			
ATACAND HCT (ORAL)	0.0%	OFF	No			
VALSARTAN HCTZ (ORAL)	0.1%	OFF	No-Generic			
TELMISARTAN HCTZ (AG) (ORAL)	0.0%	NR	No-Generic			
CANDESARTAN HCTZ (ORAL)	0.0%	NR	No-Generic			
TELMISARTAN HCTZ (ORAL)	0.0%	NR	No-Generic			
TEKTURNA (ORAL)	0.1%	OFF	No			
TEKTURNA HCT (ORAL)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

ANGIOTENSIN MODULATOR COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZOR (ORAL)	35.3%	ON	Yes			
TARKA (ORAL)	1.2%	ON	Yes			
EXFORGE HCT (ORAL)	11.5%	ON	Yes			
EXFORGE (ORAL)	25.4%	ON	Yes			
TRIBENZOR (ORAL)	17.6%	ON	Yes			
AMLODIPINE / BENAZEPRIL (ORAL)	1.2%	OFF	Yes-Generic			
TEKAMLO (ORAL)	0.0%	OFF	No			
AMTURNIDE (ORAL)	0.0%	OFF	No			
TWYNSTA (ORAL)	0.0%	OFF	No			
LOTREL (ORAL)	7.7%	ON	No			
TELMISARTAN / AMLODIPINE (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

BETA-BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BISOPROLOL HCTZ (ORAL)	0.1%	OFF	Yes-Generic			
ATENOLOL / CHLORTHALIDONE (ORAL)	1.0%	ON	Yes-Generic			
PROPRANOLOL / HCTZ (ORAL)	0.0%	OFF	No-Generic			
NADOLOL / BENDROFLUMETHIAZIDE (ORAL)	0.0%	OFF	No-Generic			
METOPROLOL / HCTZ (ORAL)	0.0%	OFF	No-Generic			
TOPROL XL (ORAL)	28.1%	ON	Yes			
ATENOLOL (ORAL)	18.1%	ON	Yes-Generic			
METOPROLOL (ORAL)	27.2%	ON	Yes-Generic			
CARVEDILOL (ORAL)	10.9%	ON	Yes-Generic			
PROPRANOLOL TABLET (ORAL)	5.5%	ON	Yes-Generic			
PROPRANOLOL SOLUTION (ORAL)	0.4%	ON	Yes-Generic			
DUTOPROL (ORAL)	0.0%	OFF	No			
LEVATOL (ORAL)	0.0%	OFF	No			
SOTALOL (ORAL)	0.7%	ON	Yes-Generic			
BISOPROLOL (ORAL)	0.1%	OFF	Yes-Generic			
ACEBUTOLOL (ORAL)	0.1%	ON	Yes-Generic			
BYSTOLIC (ORAL)	1.6%	OFF	No			
INNOPRAN XL (ORAL)	0.0%	OFF	No			
LABELALOL (ORAL)	1.1%	OFF	No-Generic			
PROPRANOLOL ER (ORAL)	3.1%	ON	Yes-Generic			
PINDOLOL (ORAL)	0.0%	OFF	No-Generic			
METOPROLOL XL (ORAL)	1.6%	OFF	No-Generic			
BETAXOLOL (ORAL)	0.0%	OFF	No-Generic			
COREG CR (ORAL)	0.1%	OFF	No			
TIMOLOL (ORAL)	0.0%	OFF	No-Generic			
NADOLOL (ORAL)	0.3%	OFF	No-Generic			

- Discussion: Kevin Izard indicated that in the written testimony packet there was a letter from an OBGYN provider advocating addition of labetalol as preferred for treatment of hypertension in pregnancy without the need to get a PA. Kevin Izard stated that it seems like the usage would not get out of hand if it was allowed as preferred. Alicia Walker questioned if labetalol is most often used in pregnancy. Rick Pope indicated that labetalol is a pregnancy C category drug.
- James Boblin stated the PA process is not onerous. He did not think that the prescriber understood the PA process. He indicated that we should keep labetalol non-preferred. All PAs are speed bumps; we need them to keep things under control. Lawrence Fleming stated that providers need to have education on the PA process.

- Catherine Decker wanted to confirm that the system was unable to allow preferred status for labetalol only during pregnancy. Staff confirmed that preferred status would allow open access for all members.

Motion 1:

- Kevin IZARD made a motion to prefer labetalol.
 - Second- Rosanne Barber
 - The vote was 3-9 in favor of the motion. Catherine Decker, Lawrence Fleming, Steve Maiké, Pat Towers, Michael Witkovsky, James Boblin, Ward Brown, Ronald Diamond, William Raduege opposed the motion.
 - Motion failed.

Motion 2:

- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - The vote was 9-3 in favor of the motion. Rosanne Barber, Kevin IZARD and Alicia Walker opposed the motion.
 - Motion passes

CALCIUM CHANNEL BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMLODIPINE (ORAL)	68.8%	ON	Yes-Generic			
DILTIAZEM TABLET (ORAL)	1.6%	ON	Yes-Generic			
VERAPAMIL TABLET (ORAL)	1.2%	ON	Yes-Generic			
VERAPAMIL TABLET ER (ORAL)	4.0%	ON	Yes-Generic			
CARDIZEM LA (ORAL)	0.2%	ON	Yes			
ISRADIPINE (ORAL)	0.2%	OFF	No-Generic			
VERAPAMIL CAPSULE ER (ORAL)	1.2%	ON	Yes-Generic			
CARDENE SR (ORAL)	0.0%	OFF	No			
NIFEDIPINE ER (ORAL)	5.8%	ON	Yes-Generic			
FELODIPINE ER (ORAL)	0.1%	OFF	No-Generic			
DILTIAZEM CAPSULE ER (ORAL)	16.3%	ON	Yes-Generic			
NIFEDIPINE IR (ORAL)	0.4%	ON	Yes-Generic			
MATZIM LA (ORAL)	0.0%	OFF	No-Generic			
VERAPAMIL ER PM (ORAL)	0.0%	OFF	No-Generic			
VERAPAMIL 360 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
NICARDIPINE (ORAL)	0.0%	OFF	No-Generic			
NISOLDIPINE (ORAL)	0.1%	OFF	No-Generic			
NIMODIPINE (ORAL)	0.0%	ON	Yes-Generic			
NYMALIZE (ORAL)	0.0%	NR	No			

- Discussion: None
- Steve Maiké made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRIGLIDE (ORAL)	0.0%	OFF	No			
NIACOR (ORAL)	0.0%	ON	Yes-Generic			
GEMFIBROZIL (ORAL)	13.8%	ON	Yes-Generic			
TRILIPIX (ORAL)	5.7%	ON	Yes			
TRICOR (ORAL)	21.8%	ON	Yes			
NIASPAN (ORAL)	15.4%	ON	Yes			
FENOFIBRATE (ANTARA) (AG) (ORAL)	0.0%	NR	No-Generic			
WELCHOL TABLET (ORAL)	1.3%	OFF	No			
COLESTIPOL TABLET (ORAL)	0.6%	OFF	Yes-Generic			
ZETIA (ORAL)	13.4%	OFF	No			
LIPOFEN (ORAL)	0.0%	OFF	No			
FENOFIBRATE TABLET (LOFIBRA) (ORAL)	19.2%	ON	Yes-Generic			
FENOFIBRIC ACID (FIBRICOR) (ORAL)	0.0%	ON	No-Generic			
CHOLESTYRAMINE/SUCROSE (ORAL)	3.9%	ON	Yes-Generic			
CHOLESTYRAMINE/ASPARTAME (ORAL)	2.2%	ON	Yes-Generic			
FIBRICOR (ORAL)	0.0%	OFF	No			
LOVAZA (ORAL)	0.9%	ON	Yes			
WELCHOL POWDER PACK (ORAL)	0.2%	OFF	No			
FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)	0.3%	OFF	No-Generic			
FENOFIBRATE TABLET (AG) (TRICOR) (ORAL)	0.3%	OFF	No-Generic			
FENOFIBRATE TABLET (TRICOR) (ORAL)	0.4%	OFF	No-Generic			
NIACIN ER (ORAL)	0.4%	NR	No-Generic			
ANTARA (ORAL)	0.0%	OFF	No			
FENOFIBRIC ACID (TRILIPIX) (ORAL)	0.0%	NR	No-Generic			
FENOFIBRATE (ANTARA) (ORAL)	0.0%	NR	No-Generic			
VASCEPA (ORAL)	0.0%	OFF	No			
FENOFIBRIC ACID (TRILIPIX) (AG) (ORAL)	0.0%	NR	No-Generic			
COLESTIPOL GRANULES (ORAL)	0.0%	OFF	No-Generic			
JUXTAPID (ORAL)	0.0%	NR	No			
KYNAMRO (SUBCUTANE.)	0.0%	NR	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	37.1%	ON	Yes-Generic			
CRESTOR (ORAL)	5.0%	OFF	No			
LOVASTATIN (ORAL)	7.3%	ON	Yes-Generic			
ALTOPREV (ORAL)	0.0%	OFF	No			
ATORVASTATIN (ORAL)	35.2%	ON	Yes-Generic			
LESCOL (ORAL)	0.4%	ON	No			
VYTORIN (ORAL)	0.2%	OFF	No			
PRAVASTATIN (ORAL)	14.2%	ON	Yes-Generic			
SIMCOR (ORAL)	0.1%	ON	No			
LESCOL XL (ORAL)	0.5%	ON	No			
LIPTRUZET (ORAL)	0.0%	NR	No			
ADVICOR (ORAL)	0.0%	OFF	No			
LIVALO (ORAL)	0.1%	OFF	No			
FLUVASTATIN (ORAL)	0.0%	OFF	No-Generic			
AMLODIPINE-ATORVASTATIN (ORAL)	0.0%	OFF	No-Generic			
CADUET (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Radeuge made a motion to accept staff recommendations as presented.
 - Second-Ward Brown

- All members were in favor of the motion
- Motion passes

PAH AGENTS, ORAL AND INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TYVASO (INHALATION)	2.8%	OFF	No			
VENTAVIS (INHALATION)	1.4%	OFF	No			
TRACLEER (ORAL)	16.8%	ON	Yes			
LETAIRIS (ORAL)	9.4%	ON	Yes			
OPSUMIT (ORAL)	0.0%	NR	No			
ADEMPAS (ORAL)	0.0%	NR	No			
SILDENAFIL (ORAL)	51.4%	ON	Yes-Generic			
ADCIRCA (ORAL)	18.2%	OFF	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - All members were in favor of the motion
 - Motion passes

ANTICOAGULANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WARFARIN (ORAL)	83.3%	ON	Yes-Generic			
ELIQUIS (ORAL)	0.2%	OFF	Yes			
PRADAXA (ORAL)	1.8%	ON	Yes			
XARELTO (ORAL)	6.3%	ON	Yes			
FRAGMIN VIAL (SUBCUTANE.)	0.0%	OFF	No			
FRAGMIN DISP SYRIN (SUBCUTANE.)	0.3%	ON	Yes			
LOVENOX VIAL (SUBCUTANE.)	0.2%	ON	Yes			
ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS)	0.0%	OFF	No-Generic			
ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS)	0.0%	OFF	No-Generic			
LOVENOX SYRINGE (SUBCUTANE.)	7.2%	ON	Yes			
ARIXTRA (SUBCUTANE.)	0.0%	OFF	No			
ENOXAPARIN SYRINGE (SUBCUTANE.)	0.4%	OFF	No-Generic			
ENOXAPARIN SYRINGE (AG) (SUBCUTANE.)	0.1%	OFF	No-Generic			
FONDAPARINUX (SUBCUTANE.)	0.1%	OFF	No-Generic			

- Discussion: Alicia Walker questioned what would be the benefit to prefer Eliquis in this class. Rick Pope indicated that it will be cost neutral to the state.
- Ward Brown stated the three newer oral products require less monitoring which can reduce transportation issues and there is an advantage because these drugs are not affected by renal function. Kevin Izard indicated that we should make things simple and the fewer restrictions the better. When members are discharged from the hospital on one of these drugs, they should be available without PA.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - The vote was 11-1 in favor of the motion. Alicia Walker opposed the motion.
 - Motion passes

PLATELET AGGREGATION INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOPIDOGREL (ORAL)	92.7%	ON	Yes-Generic			
AGGRENOX (ORAL)	5.2%	ON	Yes			
DIPYRIDAMOLE (ORAL)	0.3%	ON	Yes-Generic			
BRILINTA (ORAL)	0.3%	OFF	No			
TICLOPIDINE (ORAL)	0.2%	OFF	No-Generic			
EFFIENT (ORAL)	1.3%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLYSET (ORAL)	7.7%	ON	Yes			
ACARBOSE (ORAL)	92.3%	ON	Yes-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
JENTADUETO (ORAL)	1.6%	ON	Yes			
TRADJENTA (ORAL)	9.8%	ON	Yes			
JANUMET XR (ORAL)	2.1%	ON	Yes			
JANUMET (ORAL)	15.5%	ON	Yes			
JANUVIA (ORAL)	64.4%	ON	Yes			
KOMBIGLYZE XR (ORAL)	0.6%	OFF	No			
ONGLYZA (ORAL)	2.2%	OFF	No			
KAZANO (ORAL)	0.0%	OFF	No			
OSENI (ORAL)	0.0%	OFF	No			
NESINA (ORAL)	0.0%	OFF	No			
BYETTA PENS (SUBCUTANE.)	2.4%	ON	Yes			
SYMLIN PENS (SUBCUTANE.)	0.3%	OFF	No			
BYDUREON (SUBCUTANE.)	0.1%	OFF	No			
VICTOZA (SUBCUTANE.)	1.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMULIN 70/30 VIAL OTC (SUBCUTANE.)	2.9%	ON	Yes			
HUMALOG MIX VIAL (SUBCUTANE.)	1.1%	ON	Yes			
HUMULIN VIAL OTC (SUBCUTANE.)	5.1%	ON	Yes			
NOVOLOG MIX PEN (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG MIX PEN (SUBCUTANE.)	2.9%	ON	Yes			
NOVOLOG MIX VIAL (SUBCUTANE.)	0.0%	OFF	No			
HUMULIN 500 U/M VIAL (SUBCUTANE.)	0.7%	ON	Yes			
NOVOLIN 70/30 VIAL OTC (SUBCUTANE.)	0.0%	OFF	No			
NOVOLIN VIAL OTC (SUBCUTANE.)	0.1%	OFF	No			
HUMULIN PEN OTC (SUBCUTANE.)	1.2%	ON	Yes			
HUMULIN 70/30 PEN OTC (SUBCUTANE.)	1.8%	ON	Yes			
LEVEMIR VIAL (SUBCUTANE.)	0.6%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	1.4%	ON	Yes			
LANTUS VIAL (SUBCUTANE.)	14.6%	ON	Yes			
LANTUS SOLOSTAR PEN (SUBCUTANE.)	32.4%	ON	Yes			
HUMALOG VIAL (SUBCUTANE.)	12.1%	ON	Yes			
NOVOLOG CARTRIDGE (SUBCUTANE.)	0.1%	OFF	No			
NOVOLOG VIAL (SUBCUTANE.)	0.2%	OFF	No			
NOVOLOG PEN (SUBCUTANE.)	0.3%	OFF	No			
APIDRA VIAL (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG PEN (SUBCUTANE.)	20.0%	ON	Yes			
HUMALOG CARTRIDGE (SUBCUTANE.)	2.2%	ON	Yes			
APIDRA SOLOSTAR PEN (SUB-Q)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, MEGLITINIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRANDIN (ORAL)	83.9%	ON	Yes			
PRANDIMET (ORAL)	0.7%	OFF	No			
NATEGLINIDE (ORAL)	15.4%	OFF	No-Generic			
REPAGLINIDE (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, METFORMINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METFORMIN (ORAL)	75.0%	ON	Yes-Generic			
METFORMIN ER (GLUCOPHAGE XR) (ORAL)	20.6%	ON	Yes-Generic			
GLYBURIDE-METFORMIN (ORAL)	2.3%	ON	Yes-Generic			
RIOMET (ORAL)	0.1%	ON	Yes			
GLIPIZIDE-METFORMIN (ORAL)	0.5%	ON	Yes-Generic			
METFORMIN ER (1000MG) (ORAL)	1.5%	ON	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, SGLT2						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
INVOKANA (ORAL)	100.0%	NR	No			
FARXIGA (ORAL)	0.0%	NR	No			

- Discussion: None
- Steve Maiké made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, SULFONYLUREAS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLIMEPIRIDE (ORAL)	27.2%	ON	Yes-Generic			
GLIPIZIDE (ORAL)	30.6%	ON	Yes-Generic			
GLYBURIDE MICRONIZED (ORAL)	0.7%	ON	Yes-Generic			
CHLORPROPAMIDE (ORAL)	0.0%	ON	Yes-Generic			
GLIPIZIDE ER (ORAL)	22.6%	ON	Yes-Generic			
GLYBURIDE (ORAL)	18.9%	ON	Yes-Generic			
TOLAZAMIDE (ORAL)	0.0%	ON	No-Generic			
TOLBUTAMIDE (ORAL)	0.0%	ON	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

HYPOGLYCEMICS, TZD						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PIOGLITAZONE (ORAL)	99.1%	ON	Yes-Generic			
AVANDAMET (ORAL)	0.0%	OFF	No			
DUETACT (ORAL)	0.0%	OFF	No			
AVANDIA (ORAL)	0.0%	OFF	No			
PIOGLITAZONE / METFORMIN (ORAL)	0.5%	OFF	No-Generic			
AVANDARYL (ORAL)	0.0%	OFF	No			
ACTOPLUS MET XR (ORAL)	0.2%	OFF	No			
PIOGLITAZONE/GLIMEPIRIDE (ORAL)	0.0%	OFF	No-Generic			
ACTOPLUS MET (ORAL)	0.2%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

ANTIEMETIC/ANTIVERTIGO AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ONDANSETRON TABLETS (ORAL)	23.7%	ON	Yes-Generic			
MECLIZINE OTC (ORAL)	1.8%	ON	Yes-Generic			
METOCLOPRAMIDE TABLET (ORAL)	9.9%	ON	Yes-Generic			
PROCHLORPERAZINE (ORAL)	5.6%	ON	Yes-Generic			
MECLIZINE (ORAL)	7.5%	ON	Yes-Generic			
PROMETHAZINE SYRUP (ORAL)	1.2%	ON	Yes-Generic			
PROMETHAZINE TABLET (ORAL)	5.8%	ON	Yes-Generic			
METOCLOPRAMIDE SOLUTION (ORAL)	0.5%	ON	Yes-Generic			
ONDANSETRON ODT (ORAL)	39.3%	ON	Yes-Generic			
METOZOLV ODT (ORAL)	0.0%	OFF	No			
TRANSDERM-SCOP (TRANSDERM)	2.2%	ON	Yes			
TRIMETHOBENZAMIDE (ORAL)	0.0%	ON	Yes-Generic			
PROCHLORPERAZINE (RECTAL)	0.3%	ON	Yes-Generic			
PROMETHAZINE (RECTAL)	0.7%	ON	Yes-Generic			
GRANISETRON (ORAL)	0.0%	OFF	No-Generic			
EMEND (ORAL)	0.1%	ON	Yes			
ZUPLENZ (ORAL)	0.0%	OFF	No			
DICLEGIS (ORAL)	0.1%	NR	No			
ONDANSETRON SOLUTION (ORAL)	0.8%	ON	Yes-Generic			
PROMETHAZINE 50 MG (RECTAL)	0.0%	ON	Yes-Generic			
MARINOL (ORAL)	0.1%	ON	Yes			
GRANISOL SOLUTION (ORAL)	0.0%	OFF	No-Generic			
EMEND PACK (ORAL)	0.1%	ON	Yes			
ANZEMET (ORAL)	0.0%	OFF	No			
DRONABINOL (ORAL)	0.0%	OFF	No-Generic			
SANCUSO (TRANSDERMAL)	0.0%	OFF	No			
CESAMET (ORAL)	0.0%	OFF	No			

- Discussion: None
- Steve Maiké made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - All members were in favor of the motion
 - Motion passes

PANCREATIC ENZYMES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANCRELIPASE (AG) (ORAL)	19.6%	ON	Yes			
ZENPEP (ORAL)	41.1%	ON	Yes			
VIOKACE (ORAL)	0.4%	OFF	No			
PERTZYE (ORAL)	0.1%	OFF	No			
PANCREAZE (ORAL)	5.2%	OFF	No			
CREON (ORAL)	33.6%	OFF	No			
ULTRESA (ORAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

PROTON PUMP INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANTOPRAZOLE (ORAL)	15.3%	ON	Yes-Generic			
DEXILANT (ORAL)	0.4%	OFF	No			
PROTONIX SUSPENSION (ORAL)	0.1%	ON	Yes			
OMEPRAZOLE (ORAL)	71.2%	ON	Yes-Generic			
NEXIUM (ORAL)	2.2%	OFF	No			
NEXIUM SUSPENSION (ORAL)	0.2%	ON	Yes			
ACIPHEX TABLETS (ORAL)	7.8%	ON	No			
LANSOPRAZOLE CAPSULES (ORAL)	1.3%	OFF	No-Generic			
RABEPRAZOLE TABLETS (ORAL)	0.8%	OFF	No-Generic			
OMEPRAZOLE / SODIUM BICARBONATE (ORAL)	0.0%	OFF	No-Generic			
ESOMEPRAZOLE STRONTIUM (ORAL)	0.0%	NR	No-Generic			
PREVACID SOLUTAB (ORAL)	0.5%	OFF	No			
PRILOSEC SUSPENSION (ORAL)	0.1%	ON	Yes			
ACIPHEX SPRINKLE (ORAL)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - The vote was 11-1 in favor of the motion. Alicia Walker opposed the motion.
 - Motion passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIPENTUM (ORAL)	0.1%	OFF	No			
SULFASALAZINE (ORAL)	20.6%	ON	Yes-Generic			
SULFASALAZINE DR (ORAL)	5.0%	ON	Yes-Generic			
BALSALAZIDE (ORAL)	8.3%	ON	Yes-Generic			
APRISO (ORAL)	16.5%	ON	Yes			
DELZICOL (ORAL)	3.7%	OFF	No			
LIALDA (ORAL)	30.9%	ON	Yes			
PENTASA (ORAL)	6.1%	OFF	No			
GAZO (ORAL)	0.0%	OFF	No			
ASACOL HD (ORAL)	4.4%	OFF	No			
UCERIS (ORAL)	0.0%	OFF	No			
ROWASA (RECTAL)	0.9%	ON	Yes			
CANASA (RECTAL)	3.1%	ON	Yes			
MESALAMINE KIT (RECTAL)	0.0%	OFF	No-Generic			
MESALAMINE (RECTAL)	0.4%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

H. PYLORI TREATMENT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HELIDAC (ORAL)	1.1%	ON	Yes			
PYLERA (ORAL)	13.6%	OFF	No			
PREVPAC (ORAL)	85.2%	ON	Yes			
OMECLAMOX-PAK (ORAL)	0.0%	OFF	No			
LANSOPRAZOLE/AMOXICILLIN/CLARITHROMYCIN (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - All members were in favor of the motion
 - Motion passes

ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE TABLET (ORAL)	95.9%	ON	Yes-Generic			
NEOMYCIN (ORAL)	0.4%	ON	Yes-Generic			
TINDAMAX (ORAL)	0.0%	OFF	No			
FLAGYL ER (ORAL)	0.0%	OFF	No			
VANCOCIN HCL (ORAL)	1.1%	ON	Yes			
ALINIA SUSPENSION (ORAL)	0.1%	ON	Yes			
METRONIDAZOLE CAPSULE (ORAL)	0.0%	OFF	No-Generic			
TINDAZOLE (ORAL)	0.2%	OFF	No-Generic			
ALINIA TABLET (ORAL)	0.2%	ON	Yes			
VANCOMYCIN HCL (ORAL)	0.1%	OFF	No-Generic			
XIFAXAN (ORAL)	2.0%	OFF	No			
DIFICID TABLET (ORAL)	0.1%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

ANTIBIOTICS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETHKIS (INHALATION)	0.0%	NR	Yes			
TOBI (INHALATION)	73.6%	ON	Yes			
TOBIPODHALER (INHALATION)	0.0%	NR	No			
CAYSTON (INHALATION)	7.7%	OFF	No			
TOBRAMYCIN SOLUTION (INHALATION)	18.7%	NR	No-Generic			

- Discussion: There was discussion among committee members regarding the dosing of inhaled antibiotics. Catherine Decker wanted to allow daily dosing, alternating the antibiotic every other month, known as continuous alternating therapy. Current policy is to only allow one antibiotic at a time alternating one month on and one month off. Catherine wanted consideration of special criteria to allow continuous alternating therapy. There was extensive discussion, but no consensus regarding what would qualify for the special criteria. Rick Pope stated the 2013 American Thoracic Society Guidelines did not include continuous alternating therapy. Ronald Diamond stated that we should allow individual cases to be approved that are not based only on guidelines, but other sources as well. James Boblin stated there is no current evidence that suggests the alternating therapy is standard of care. He further indicated that we should leave criteria as is and review in one year.
- Pat Towers commented that the role of the PA Committee is to decide on PDL preferred and non-preferred status of drugs and not specific PA criteria. Rachel Currans-Henry agreed, but also stated that feedback from the Committee is taken into consideration when PA criteria are developed.
- Rosanne Barber commented that Tobi Podhaler should be preferred, based on public testimony. It could lead to better compliance. She stated that there is so much treatment for Cystic Fibrosis, if this can make it easier, it should be allowed.
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - The vote was 11-1 in favor of the motion. Rosanne Barber opposed the motion.
 - Motion passes

ANTIBIOTICS, VAGINAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VANDAZOLE (VAGINAL)	3.4%	ON	Yes			
METRONIDAZOLE (VAGINAL)	83.0%	ON	Yes-Generic			
CLEOCIN OVULES (VAGINAL)	3.3%	ON	Yes			
CLINDESSE (VAGINAL)	0.7%	OFF	No			
CLINDAMYCIN (VAGINAL)	9.6%	ON	Yes-Generic			

- Discussion: None
- Steve Maik made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

ANTIFUNGALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KETOCONAZOLE (ORAL)	0.8%	ON	Yes-Generic			
FLUCONAZOLE TABLET (ORAL)	68.4%	ON	Yes-Generic			
TERBINAFININE (ORAL)	5.6%	ON	Yes-Generic			
NYSTATIN SUSPENSION (ORAL)	17.0%	ON	Yes-Generic			
CLOTRIMAZOLE (MUCOUS MEM)	0.1%	OFF	Yes-Generic			
FLUCONAZOLE SUSPENSION (ORAL)	2.8%	ON	Yes-Generic			
NYSTATIN TABLET (ORAL)	0.3%	ON	Yes-Generic			
GRISEFULVIN TABLETS (ORAL)	0.0%	OFF	Yes-Generic			
NYSTATIN POWDER (ORAL)	0.3%	ON	Yes-Generic			
GRISEFULVIN SUSPENSION (ORAL)	3.7%	ON	Yes-Generic			
LAMISIL GRANULES (ORAL)	0.0%	OFF	No			
GRIS-PEG (ORAL)	0.5%	ON	Yes			
GRISEFULVIN ULTRAMICROSIZE (ORAL)	0.0%	OFF	No-Generic			
ONMEL (ORAL)	0.0%	OFF	No			
GRIFULVIN V TABLETS (ORAL)	0.0%	OFF	No-Generic			
ORAVIG (BUCCAL)	0.0%	OFF	No			
SPORANOX SOLUTION (ORAL)	0.1%	OFF	No			
VFEND SUSPENSION (ORAL)	0.0%	OFF	No			
ITRACONAZOLE (ORAL)	0.3%	ON	Yes			
VORICONAZOLE SUSPENSION (ORAL)	0.0%	NR	No-Generic			
VORICONAZOLE TABLETS (ORAL)	0.2%	OFF	No-Generic			
FLUCYTOSINE (ORAL)	0.0%	OFF	No-Generic			
NOXAFIL SUSPENSION (ORAL)	0.0%	NR	No			
NOXAFIL TABLET (ORAL)	0.0%	OFF	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - All members were in favor of the motion
 - Motion passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR TABLET (ORAL)	20.4%	ON	Yes-Generic			
ACYCLOVIR CAPSULE (ORAL)	3.4%	ON	Yes-Generic			
VALACYCLOVIR (ORAL)	60.0%	ON	Yes-Generic			
ACYCLOVIR SUSPENSION (ORAL)	2.1%	ON	Yes-Generic			
FAMCICLOVIR (ORAL)	0.1%	OFF	No-Generic			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
RELENZA (INHALATION)	0.0%	ON	Yes			
TAMIFLU CAPSULE (ORAL)	7.5%	ON	Yes			
AMANTADINE CAPSULE (ORAL)	0.2%	OFF	Yes-Generic			
AMANTADINE TABLET (ORAL)	3.1%	ON	Yes-Generic			
AMANTADINE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
TAMIFLU SUSPENSION (ORAL)	2.8%	ON	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CEPHALEXIN CAPSULE (ORAL)	20.6%	ON	Yes-Generic			
AUGMENTIN 125 SUSPENSION (ORAL)	0.0%	ON	Yes			
CEFADROXIL CAPSULE (ORAL)	1.4%	ON	Yes-Generic			
CEPHALEXIN TABLET (ORAL)	0.0%	ON	Yes-Generic			
CEFUROXIME TABLET (ORAL)	3.8%	ON	Yes-Generic			
CEPHALEXIN SUSPENSION (ORAL)	5.6%	ON	Yes-Generic			
AMOXICILLIN/CLAV TABLET (ORAL)	26.8%	ON	Yes-Generic			
SUPRAX TABLET (ORAL)	0.5%	ON	Yes			
SUPRAX SUSPENSION (ORAL)	0.3%	ON	Yes			
AMOXICILLIN/CLAV CHEW TABLET (ORAL)	0.4%	ON	Yes-Generic			
AMOXICILLIN/CLAV SUSPENSION (ORAL)	17.9%	ON	Yes-Generic			
CEFPROZIL TABLET (ORAL)	0.7%	ON	Yes-Generic			
CEFACTOR CAPSULE (ORAL)	0.0%	ON	Yes-Generic			
SUPRAX TAB CHEW (ORAL)	0.0%	OFF	No			
CEFPROZIL SUSPENSION (ORAL)	1.8%	ON	Yes-Generic			
CEFACTOR TABLET ER (ORAL)	0.0%	OFF	No-Generic			
SUPRAX CAPSULE (ORAL)	0.0%	NR	Yes			
CEFDINIR SUSPENSION (ORAL)	14.9%	ON	Yes-Generic			
CEFADROXIL SUSPENSION (ORAL)	0.3%	ON	Yes-Generic			
CEFDINIR CAPSULE (ORAL)	4.7%	ON	Yes-Generic			
CEFTIN SUSPENSION (ORAL)	0.3%	ON	Yes			
CEDAX CAPSULE (ORAL)	0.0%	OFF	No			
CEFADROXIL TABLET (ORAL)	0.0%	ON	Yes-Generic			
CEFPODOXIME TABLET (ORAL)	0.0%	OFF	No-Generic			
AMOXICILLIN/CLAV XR (ORAL)	0.0%	OFF	No-Generic			
CEDAX SUSPENSION (ORAL)	0.0%	OFF	No			
CEFTIBUTEN CAPSULE (AG) (ORAL)	0.0%	NR	No-Generic			
CEFPODOXIME SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
CEFACTOR SUSPENSION (ORAL)	0.0%	ON	Yes-Generic			
CEFTIBUTEN SUSPENSION (AG) (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

PENICILLINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMOXICILLIN TABLET (ORAL)	9.5%	ON	Yes-Generic			
AMOXICILLIN CAPSULE (ORAL)	25.4%	ON	Yes-Generic			
AMOXICILLIN SUSPENSION (ORAL)	51.9%	ON	Yes-Generic			
PENICILLIN V POTASSIUM TABLET (ORAL)	8.9%	ON	Yes-Generic			
AMPICILLIN CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
PENICILLIN V POTASSIUM SUSPENSION (ORAL)	1.7%	ON	Yes-Generic			
AMOXICILLIN TAB CHEW (ORAL)	1.7%	ON	Yes-Generic			
DICLOXACILLIN (ORAL)	0.7%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

FLUOROQUINOLONES, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN TABLET (ORAL)	64.0%	ON	Yes-Generic			
LEVOFLOXACIN TABLET (ORAL)	35.5%	ON	Yes-Generic			
NOROXIN (ORAL)	0.0%	OFF	No			
AVELOX (ORAL)	0.2%	OFF	No			
CIPRO SUSPENSION (ORAL)	0.2%	OFF	No			
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	No-Generic			
OFLOXACIN (ORAL)	0.0%	OFF	No-Generic			
FACTIVE (ORAL)	0.0%	OFF	No-Generic			
LEVOFLOXACIN SOLUTION (ORAL)	0.1%	OFF	No			
MOXIFLOXACIN (AG) (ORAL)	0.0%	NR	No-Generic			
MOXIFLOXACIN (ORAL)	0.0%	NR	No-Generic			

- Discussion: There was discussion among committee members regarding the high cost of generic moxifloxaicin. Rick Pope responded that brand Avelox and generic moxifloxacin are both non-preferred. Rick stated that new generics are often more expensive than the brand. The price of the generic usually goes down after 6 months but it can be longer.
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - All members were in favor of the motion
 - Motion passes

MACROLIDES/KETOLIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZITHROMYCIN TABLET (ORAL)	61.7%	ON	Yes-Generic			
AZITHROMYCIN PACKET (ORAL)	0.3%	ON	Yes-Generic			
AZITHROMYCIN SUSPENSION (ORAL)	34.6%	ON	Yes-Generic			
ZMAX (ORAL)	0.0%	OFF	No			
CLARITHROMYCIN TABLET (ORAL)	2.0%	ON	Yes-Generic			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	No-Generic			
KETEK (ORAL)	0.0%	OFF	No			
CLARITHROMYCIN SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
ERYTHROMYCIN BASE TABLET (ORAL)	0.5%	ON	Yes-Generic			
ERYTHROCIN (ORAL)	0.1%	ON	Yes-Generic			
E.E.S. 400 TABLET (ORAL)	0.1%	ON	Yes-Generic			
ERYTHROMYCIN BASE CAPSULE DR (ORAL)	0.0%	OFF	No-Generic			
E.E.S. 200 SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - All members were in favor of the motion
 - Motion passes

TETRACYCLINES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TETRACYCLINE (ORAL)	0.1%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL)	0.1%	ON	Yes-Generic			
VIBRAMYCIN SUSPENSION (ORAL)	0.1%	OFF	No			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)	3.5%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)	41.5%	ON	Yes-Generic			
MINOCYCLINE CAPSULES (ORAL)	31.5%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL)	5.5%	ON	Yes-Generic			
DOXYCYCLINE HYCLATE TABLET (ORAL)	0.8%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE TABLET (ORAL)	16.3%	ON	Yes-Generic			
ORACEA (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE SUSPENSION (ORAL)	0.0%	NR	No-Generic			
VIBRAMYCIN SYRUP (ORAL)	0.1%	OFF	No			
DOXYCYCLINE HYCLATE CAPSULE (ORAL)	0.3%	OFF	No-Generic			
MINOCYCLINE TABLETS (ORAL)	0.0%	OFF	No-Generic			
MINOCYCLINE ER (ORAL)	0.0%	OFF	No-Generic			
DORYX (ORAL)	0.0%	OFF	No			
DOXYCYCLINE HYCLATE TABLET DR (ORAL)	0.0%	OFF	No-Generic			
DEMECLOCYCLINE (ORAL)	0.1%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

ACNE AGENTS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BENZACLIN W/PUMP (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE 10% CREAM OTC (TOPICAL)	0.0%	ON	Yes-Generic			
BENZOYL PEROXIDE LOTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
AKNE-MYCIN (TOPICAL)	0.0%	OFF	No			
KLARON (TOPICAL)	0.0%	OFF	No			
ATRALIN (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE 5% WASH OTC (TOPICAL)	2.7%	ON	Yes-Generic			
AZELEX (TOPICAL)	1.3%	ON	Yes			
BENZOYL PEROXIDE GEL OTC (TOPICAL)	11.5%	ON	Yes-Generic			
BENZOYL PEROXIDE GEL (TOPICAL)	0.1%	ON	Yes-Generic			
BENZOYL PEROXIDE 10% WASH OTC (TOPICAL)	2.0%	ON	Yes-Generic			
DIFFERIN LOTION (TOPICAL)	0.2%	ON	Yes			
TAZORAC CREAM (TOPICAL)	0.4%	OFF	No			
ZIANA (TOPICAL)	0.0%	OFF	No			
DIFFERIN CREAM (TOPICAL)	3.5%	ON	Yes			
ERYTHROMYCIN GEL (TOPICAL)	2.1%	ON	Yes-Generic			
EPIDUO (TOPICAL)	0.1%	OFF	Yes			
TAZORAC GEL (TOPICAL)	0.1%	OFF	No			
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	0.2%	OFF	No-Generic			
CERISA (TOPICAL)	0.0%	OFF	No-Generic			
AVITA CREAM (TOPICAL)	0.0%	OFF	No			
AVITA GEL (TOPICAL)	0.0%	OFF	No			
BENZACLIN (TOPICAL)	0.0%	OFF	No			
TRETINON CREAM (TOPICAL)	16.9%	ON	Yes-Generic			
ERYTHROMYCIN SOLUTION (TOPICAL)	1.1%	ON	Yes-Generic			
TRETINON GEL (TOPICAL)	5.1%	ON	Yes-Generic			
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	6.5%	ON	Yes-Generic			
BENZAMYCIN (TOPICAL)	0.0%	OFF	No			
BP 10-1 (TOPICAL)	0.0%	OFF	No-Generic			
BENZOYL PEROXIDE CLEANSER (TOPICAL)	0.0%	ON	Yes-Generic			
DIFFERIN GEL (TOPICAL)	8.5%	ON	Yes			
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	11.6%	ON	Yes-Generic			
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	21.0%	ON	Yes-Generic			
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.1%	OFF	No-Generic			
SULFACETAMIDE SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
CLEOCIN T SOLUTION (TOPICAL)	0.0%	ON	No			
CLINDAGEL (TOPICAL)	0.0%	OFF	No			
SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE SODIUM/SULFUR (TOPICAL)	0.0%	OFF	No-Generic			
TRETINON MICROSPHERES GEL (AG) (TOPICAL)	0.1%	NR	No-Generic			
SULFACETAMIDE CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
RETIN-A MICRO (TOPICAL)	4.0%	ON	No			
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL (TOPICAL)	0.0%	OFF	No-Generic			
BENZOYL PEROXIDE FOAM (TOPICAL)	0.0%	OFF	No-Generic			
TRETINON MICROSPHERES GEL PUMP (AG) (TOPICAL)	0.0%	NR	No-Generic			
CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)	0.1%	OFF	No-Generic			
ADAPALENE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
VELTIN (TOPICAL)	0.0%	OFF	No			
SSS 10-4 (TOPICAL)	0.0%	OFF	No-Generic			
ACZONE (TOPICAL)	0.3%	OFF	No			
BENZOYL PEROXIDE MICROSPHERES CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
CLINDAMYCIN / BENZOYL PEROXIDE (BENZACLIN) (TOPICAL)	0.2%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	0.0%	OFF	No-Generic			
AVAR CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
OVACE PLUS WASH (TOPICAL)	0.0%	OFF	No			
FABIOR (TOPICAL)	0.0%	NR	No			
TRETINON MICROSPHERES GEL (TOPICAL)	0.1%	NR	No-Generic			
TRETINON MICROSPHERES GEL PUMP (TOPICAL)	0.0%	NR	No-Generic			

- Discussion: Alicia Walker questioned what the benefit would be to preferring Epiduo in this class. Rick Pope stated that it gives the option of another preferred product, and is financially in line with other preferred acne products.
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second-Ronald Diamond
 - The vote was 11-1 in favor of the motion. Alicia Walker opposed the motion.
 - Motion passes

ANTIBIOTICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BACTROBAN CREAM (TOPICAL)	0.0%	OFF	No			
DOUBLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	0.1%	ON	Yes-Generic			
NEOMYCIN / POLYMYXIN / PRAMOXINE (TOPICAL)	0.0%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	10.7%	ON	Yes-Generic			
BACITRACIN OTC (TOPICAL)	6.9%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC (TOPICAL)	0.0%	ON	Yes-Generic			
BACITRACIN/POLYMYXIN OTC (TOPICAL)	1.0%	ON	Yes-Generic			
MUPIROCIN OINTMENT (TOPICAL)	79.0%	ON	Yes-Generic			
GENTAMICIN CREAM (TOPICAL)	1.0%	ON	No-Generic			
GENTAMICIN OINTMENT (TOPICAL)	1.2%	ON	No-Generic			
CENTANY (TOPICAL)	0.0%	OFF	No			
MUPIROCIN CREAM (TOPICAL)	0.0%	OFF	No-Generic			
ALTABAX (TOPICAL)	0.0%	OFF	No			
MUPIROCIN CREAM (AG) (TOPICAL)	0.1%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOLNAFTATE CREAM OTC (TOPICAL)	0.1%	ON	Yes-Generic			
TOLNAFTATE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
MICONAZOLE CREAM OTC (TOPICAL)	2.0%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM RX (TOPICAL)	12.3%	ON	Yes-Generic			
TOLNAFTATE POWDER OTC (TOPICAL)	0.1%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM OTC (TOPICAL)	6.4%	ON	Yes-Generic			
MICONAZOLE OINT OTC (TOPICAL)	0.0%	ON	Yes-Generic			
TINACTIN CREAM OTC (TOPICAL)	0.0%	ON	Yes			
MICONAZOLE POWDER OTC (TOPICAL)	0.5%	ON	Yes-Generic			
CICLOPIROX SOLUTION (TOPICAL)	0.1%	OFF	No-Generic			
CLOTRIMAZOLE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
OXISTAT CREAM (TOPICAL)	0.0%	OFF	No			
ECONAZOLE (TOPICAL)	0.1%	OFF	No-Generic			
CLOTRIMAZOLE SOLUTION RX (TOPICAL)	0.4%	ON	Yes-Generic			
KETOCONAZOLE CREAM (TOPICAL)	10.7%	ON	Yes-Generic			
OXISTAT LOTION (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE SHAMPOO (TOPICAL)	11.4%	ON	Yes-Generic			
NYSTATIN CREAM (TOPICAL)	19.8%	ON	Yes-Generic			
NYSTATIN OINT (TOPICAL)	9.9%	ON	Yes-Generic			
MENTAX (TOPICAL)	0.0%	OFF	No			
CICLOPIROX CREAM (TOPICAL)	0.0%	OFF	No-Generic			
CICLOPIROX SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
VUSION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)	10.5%	ON	Yes-Generic			
EXELDERM SOLUTION (TOPICAL)	0.0%	OFF	No			
NYSTATIN POWDER (TOPICAL)	9.5%	ON	Yes-Generic			
NAFTIN CREAM (TOPICAL)	0.0%	OFF	No			
ERTACZO (TOPICAL)	0.0%	OFF	No			
CICLOPIROX GEL (TOPICAL)	0.0%	OFF	No-Generic			
EXELDERM CREAM (TOPICAL)	0.0%	OFF	No			
NAFTIN GEL (TOPICAL)	0.0%	OFF	No			
NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)	4.5%	ON	Yes-Generic			
NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)	1.1%	ON	Yes-Generic			
CLOTRIMAZOLE-BETAMETHASONE LOTION (TOPICAL)	0.5%	ON	Yes-Generic			
CNL 8 KIT (TOPICAL)	0.0%	OFF	No			
LUZU (TOPICAL)	0.0%	NR	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

ANTIPARASITICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ULESFIA (TOPICAL)	1.0%	ON	Yes			
PERMETHRIN OTC (TOPICAL)	22.1%	ON	Yes-Generic			
SKLICE (TOPICAL)	0.6%	OFF	Yes			
NATROBA (TOPICAL)	0.0%	OFF	Yes			
EURAX CREAM (TOPICAL)	0.5%	ON	Yes			
LINDANE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
PERMETHRIN CREAM (TOPICAL)	67.0%	ON	Yes-Generic			
MALATHION BRAND (TOPICAL)	8.7%	ON	Yes-Generic			
LINDANE SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
OVIDE (TOPICAL)	0.0%	OFF	No			
SPINOSAD (TOPICAL)	0.0%	OFF	No-Generic			
EURAX LOTION (TOPICAL)	0.0%	OFF	No			

- Discussion: There was discussion among committee members if permethrin resistance exists in Wisconsin. During public testimony one of the speakers indicated that resistance has been documented in Reeseville, WI. Rick Pope commented that he believes permethrin will remain the drug of first choice and we will not see a large shift to the newer agents.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

ANTIVIRALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOVIRAX CREAM (TOPICAL)	0.0%	OFF	Yes			
DENAVIR (TOPICAL)	29.0%	ON	No			
XERESE (TOPICAL)	0.0%	OFF	No			
ACYCLOVIR OINTMENT (TOPICAL)	0.3%	NR	Yes-Generic			
ACYCLOVIR OINTMENT (AG) (TOPICAL)	0.2%	NR	Yes-Generic			
ZOVIRAX OINTMENT (TOPICAL)	70.5%	ON	No			

- Discussion: None
- Steve Maie made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

MISCELLANEOUS, ANALGESICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASPIRIN TABLET OTC (ORAL)	72.3%	ON	Yes-Generic			
ASPIRIN TAB CHEW OTC (ORAL)	23.7%	ON	Yes-Generic			
BUTALBITAL/APA/CAFFEINE (ORAL)	3.6%	OFF	No-Generic			
ACETAMINOPHEN/BUTALBITAL (ORAL)	0.1%	OFF	No-Generic			
BUTALBITAL/ASA/CAFFEINE (ORAL)	0.3%	OFF	No-Generic			
BUPAP (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.

- o Second-Ward Brown
- o All members were in favor of the motion
- o Motion passes

ANALGESICS, NARCOTICS LONG						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHADONE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
METHADONE SOL TABLET (ORAL)	0.0%	ON	Yes-Generic			
METHADONE CONC (ORAL)	3.7%	ON	Yes-Generic			
METHADONE TABLET (ORAL)	15.3%	ON	Yes-Generic			
KADIAN (ORAL)	0.2%	OFF	Yes			
MORPHINE ER TABLET (ORAL)	36.7%	ON	Yes-Generic			
CONZIP (ORAL)	0.0%	OFF	No			
FENTANYL (TRANSDERM)	22.8%	ON	Yes-Generic			
BUTRANS (TRANSDERM)	3.1%	ON	Yes			
TRAMADOL ER (ORAL)	0.4%	OFF	No-Generic			
TRAMADOL ER (GENERIC RYZOLT ER) (ORAL)	0.0%	OFF	No-Generic			
NUCYN TA ER (ORAL)	0.4%	OFF	No			
OXYMORPHONE ER (ORAL)	0.2%	OFF	No-Generic			
OXYCONTIN (ORAL)	15.3%	OFF	No			
OPANA ER (ORAL)	1.0%	OFF	No			
AVINZA (ORAL)	0.1%	OFF	No			
MORPHINE ER CAPSULE (AVINZA) (ORAL)	0.0%	NR	No-Generic			
MORPHINE ER CAPSULE (KADIAN) (ORAL)	0.3%	OFF	No-Generic			
ZOXYDOL ER (ORAL)	0.0%	NR	No			
EXALGO (ORAL)	0.3%	OFF	No			

- Discussion: Alicia Walker stated that she did not see a benefit to Kadian being added as preferred.
- William Raduege made a motion to accept staff recommendations as presented.
 - o Second-Rosanne Barber
 - o The vote was 10-2 in favor of the motion. Alicia Walker and Michael Witkovsky opposed the motion.
 - o Motion passes

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
TRAMADOL (ORAL)	17.5%	ON	Yes-Generic			
MEPERIDINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
APAP / CODEINE ELIXIR (ORAL)	0.6%	ON	Yes-Generic			
MORPHINE SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
APAP / CODEINE TABLET (ORAL)	6.0%	ON	Yes-Generic			
HYDROCODONE / APAP TABLET (ORAL)	41.5%	ON	Yes-Generic			
MORPHINE IR TABLET (ORAL)	0.7%	ON	Yes-Generic			
MORPHINE CONC SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
OXYCODONE / ASA BRAND (ORAL)	0.0%	OFF	No			
BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL)	0.0%	OFF	No-Generic			
MEPERIDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
CODEINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
CODEINE (ORAL)	0.1%	ON	Yes-Generic			
HYDROMORPHONE TABLET (ORAL)	0.7%	ON	Yes-Generic			
HYDROCODONE / IBUPROFEN (ORAL)	0.4%	ON	Yes-Generic			
OXYCODONE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
ZAMICET (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE / APAP TABLET (ORAL)	16.6%	ON	Yes-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Generic			
BUTORPHANOL TARTRATE (NASAL)	0.0%	OFF	No-Generic			
OXYCODONE TABLET (ORAL)	14.8%	ON	Yes-Generic			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.0%	OFF	No-Generic			
IBUDONE (ORAL)	0.0%	OFF	No-Generic			
MORPHINE SUPPOSITORIES (RECTAL)	0.0%	ON	Yes-Generic			
REPREXAIN (ORAL)	0.0%	OFF	No-Generic			
HYDROCODONE / APAP SOLUTION (ORAL)	0.4%	ON	Yes-Generic			
HYCET (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE CAPSULE (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE LIQUID (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE / ASA (ORAL)	0.0%	OFF	No-Generic			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic			
DIHYDROCODEINE / ASA / CAFFEINE (AG) (ORAL)	0.0%	NR	No-Generic			
NUCYNTA (ORAL)	0.1%	OFF	No			
FIORICET / CODEINE (ORAL)	0.0%	OFF	No-Generic			
OXECTA (ORAL)	0.0%	OFF	No			
CARISOPRODOL COMPOUND-CODEINE (ORAL)	0.0%	OFF	No-Generic			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Generic			
CAPITAL W-CODEINE (ORAL)	0.0%	ON	Yes-Generic			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	OFF	No-Generic			
OXYMORPHONE (ORAL)	0.1%	OFF	No-Generic			
XODOL (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE CONC (ORAL)	0.0%	OFF	No-Generic			
PRIMLEV (ORAL)	0.0%	OFF	No-Generic			
SUBSYS (SUBLINGUAL)	0.0%	OFF	No			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			
FENTORA (BUCCAL)	0.0%	OFF	No			
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

OPIATE DEPENDENCE TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SUBOXONE FILM (SUBLINGUAL)	90.6%	ON	Yes			
BUPRENORPHINE HCL (SUBLINGUAL)	8.9%	ON	No-Generic			
ZUSOLV (SUBLINGUAL)	0.0%	NR	No			
BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)	0.4%	NR	No-Generic			

- Discussion: Ronald Diamond inquired why there is so little price competition within this drug class. Rick stated that the manufacturers may not see it as profitable. Michael Witkovsky wanted to confirm that buprenorphine monotherapy would be available for pregnant women. Lynn Radmer confirmed that buprenorphine is not preferred, but is available for pregnant women through STAT-PA.
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - All members were in favor of the motion
 - Motion passes

ANTIMIGRAINE AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RIZATRIPTAN TABLET (AG) (ORAL)	0.3%	ON	Yes-Generic			
IMITREX (NASAL)	2.5%	ON	Yes			
RELPAX (ORAL)	7.5%	ON	Yes			
IMITREX KIT (SUBCUTANE.)	5.0%	ON	Yes			
SUMATRIPTAN (ORAL)	65.2%	ON	Yes-Generic			
RIZATRIPTAN ODT (ORAL)	0.7%	OFF	Yes-Generic			
RIZATRIPTAN TABLET (ORAL)	7.6%	ON	Yes-Generic			
ZOLMITRIPTAN ODT (AG) (ORAL)	0.1%	NR	No-Generic			
AXERT (ORAL)	0.3%	OFF	No			
NARATRIPTAN (ORAL)	8.7%	ON	No-Generic			
ZOLMITRIPTAN TABLET (AG) (ORAL)	0.2%	NR	No-Generic			
FROVA (ORAL)	0.2%	OFF	No			
ZOLMITRIPTAN TABLET (ORAL)	0.2%	NR	No-Generic			
ZOLMITRIPTAN ODT (ORAL)	0.1%	NR	No-Generic			
SUMATRIPTAN DISP SYRIN (SUBCUTANE.)	0.0%	OFF	No-Generic			
TREXIMET (ORAL)	0.2%	OFF	No			
SUMATRIPTAN (NASAL)	0.3%	OFF	No-Generic			
ALSUMA (SUBCUTANEOUS)	0.0%	OFF	No			
IMITREX VIAL (SUBCUTANE.)	0.1%	ON	Yes			
RIZATRIPTAN ODT (AG) (ORAL)	0.2%	OFF	No-Generic			
SUMATRIPTAN VIAL (SUBCUTANE.)	0.0%	OFF	No-Generic			
SUMATRIPTAN KIT (SUN) (SUBCUTANE.)	0.4%	OFF	No-Generic			
SUMATRIPTAN KIT (SUBCUTANE.)	0.3%	OFF	No-Generic			
SUMAVEL DOSEPRO (SUBCUTANE.)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - All members were in favor of the motion
 - Motion passes

SKELETAL MUSCLE RELAXANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CYCLOBENZAPRINE (ORAL)	58.5%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	1.6%	OFF	No-Generic			
BACLOFEN (ORAL)	15.0%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.5%	ON	Yes-Generic			
METHOCARBAMOL (ORAL)	5.8%	ON	Yes-Generic			
TIZANIDINE TABLETS (ORAL)	17.4%	ON	Yes-Generic			
ORPHENADRINE (ORAL)	0.1%	OFF	No-Generic			
CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic			
DANTROLENE SODIUM (ORAL)	0.4%	ON	Yes-Generic			
SOMA 250 MG (ORAL)	0.0%	OFF	No			
CARISOPRODOL 250 MG (ORAL)	0.1%	OFF	No-Generic			
LORZONE (ORAL)	0.0%	OFF	No			
AMRIX (ORAL)	0.0%	OFF	No			
METAXALONE (ORAL)	0.5%	OFF	No-Generic			
TIZANIDINE CAPSULES (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - All members were in favor of the motion
 - Motion passes

BLADDER RELAXANT PREPARATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OXYBUTYNIN TABLET (ORAL)	37.5%	ON	Yes-Generic			
OXYTROL FOR WOMEN OTC (TRANSDERMAL)	0.0%	OFF	No			
OXYBUTYNIN SYRUP (ORAL)	2.1%	ON	Yes-Generic			
SANCTURA XR (ORAL)	0.1%	OFF	No			
OXYTROL (TRANSDERM.)	0.3%	OFF	No			
VESICARE (ORAL)	40.6%	ON	Yes			
OXYBUTYNIN ER (ORAL)	4.8%	OFF	Yes-Generic			
TOVIAZ (ORAL)	9.6%	ON	Yes			
ENABLEX (ORAL)	0.9%	OFF	No			
SANCTURA (ORAL)	0.0%	OFF	No			
GELNIQUE (TRANSDERM.)	0.1%	OFF	No			
DETROL LA (ORAL)	1.9%	OFF	No			
GELNIQUE GEL MD PMP (TRANSDERMAL)	0.1%	OFF	No			
TROSPIMUM (ORAL)	0.3%	OFF	No-Generic			
TOLTERODINE (ORAL)	0.2%	OFF	No-Generic			
TROSPIMUM ER (ORAL)	0.2%	OFF	No-Generic			
TOLTERODINE ER (AG) (ORAL)	0.0%	NR	No-Generic			
MYRBETRIQ (ORAL)	1.3%	OFF	No			
TOLTERODINE ER (ORAL)	0.0%	NR	No-Generic			
DETROL (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

BONE RESORPTION SUPPRESSION AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALENDRONATE TABLETS (ORAL)	89.1%	ON	Yes-Generic			
BINOSTO (ORAL)	0.0%	OFF	No			
FORTICAL (NASAL)	3.6%	ON	Yes			
ATELVIA (ORAL)	0.1%	OFF	No			
ACTONEL (ORAL)	1.3%	OFF	No			
FOSAMAX PLUS D (ORAL)	0.1%	OFF	No			
EVISTA (ORAL)	3.3%	OFF	No			
BONIVA (ORAL)	0.1%	OFF	No			
ALENDRONATE SOLUTION (ORAL)	0.0%	NR	No-Generic			
CALCITONIN SALMON (NASAL)	0.7%	OFF	No-Generic			
IBANDRONATE TABLETS (ORAL)	1.4%	OFF	No-Generic			
MIACALCIN (NASAL)	0.2%	OFF	No			
ETIDRONATE DISODIUM (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - All members were in favor of the motion
 - Motion passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPOGEN (INJECTION)	0.7%	OFF	No			
ARANESP VIAL (INJECTION)	6.7%	ON	Yes			
ARANESP DISP SYRIN (INJECTION)	22.1%	ON	Yes			
PROCRIT (INJECTION)	70.5%	ON	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Kevin Izard
 - All members were in favor of the motion
 - Motion passes

GROWTH HORMONE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SAIZEN CARTRIDGE (INJECTION)	0.0%	OFF	No			
OMNITROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
SAIZEN VIAL (INJECTION)	0.0%	OFF	No			
NUTROPIN AQ CARTRIDGE (INJECTION)	9.6%	ON	Yes			
NORDITROPIN PEN (INJECTION)	90.1%	ON	Yes			
TEV-TROPIN VIAL (INJECTION)	0.0%	OFF	No			
OMNITROPE VIAL (INJECTION)	0.0%	OFF	No			
GENOTROPIN CARTRIDGE (INJECTION)	0.0%	OFF	No			
HUMATROPE VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
GENOTROPIN DISP SYRIN (INJECTION)	0.3%	OFF	No			
SEROSTIM VIAL (INJECTION)	0.0%	OFF	No			
ZORBIVIVE VIAL (INJECTION)	0.0%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - All members were in favor of the motion
 - Motion passes

ANDROGENIC AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TESTIM (TRANSDERM.)	5.9%	ON	Yes			
ANDROGEL GEL PACKET (TRANSDERM.)	33.0%	ON	Yes			
ANDROGEL GEL PUMP (TRANSDERM)	56.7%	ON	Yes			
FORTESTA (TRANSDERM)	0.0%	OFF	No			
ANDRODERM (TRANSDERM)	3.0%	OFF	No			
AXIRON (TRANSDERM)	1.5%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TAMSULOSIN (ORAL)	56.0%	ON	Yes-Generic			
FINASTERIDE (ORAL)	21.9%	ON	Yes-Generic			
ALFUZOSIN (ORAL)	0.7%	ON	Yes-Generic			
TERAZOSIN (ORAL)	6.5%	ON	Yes-Generic			
CARDURA XL (ORAL)	0.0%	OFF	No			
AVODART (ORAL)	0.6%	OFF	No			
RAPAFLO (ORAL)	0.2%	OFF	No			
DOXAZOSIN (ORAL)	13.9%	ON	No-Generic			
JALYN (ORAL)	0.1%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - All members were in favor of the motion
 - Motion passes

PHOSPHATE BINDERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PHOSLYRA (ORAL)	0.7%	OFF	Yes			
ELIPHOS (ORAL)	0.0%	OFF	Yes-Generic			
RENAGEL (ORAL)	39.8%	ON	Yes			
CALCIUM ACETATE TABLET (ORAL)	0.7%	ON	Yes-Generic			
CALCIUM ACETATE CAPSULE (ORAL)	44.4%	ON	No-Generic			
REVELA TABLET (ORAL)	6.2%	OFF	No			
FOSRENOL (ORAL)	6.4%	ON	No			
REVELA POWDER PACK (ORAL)	1.8%	OFF	No			
VELPHORO (ORAL)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - All members were in favor of the motion
 - Motion passes

HEPATITIS B AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPIVIR HBV SOLUTION (ORAL)	0.0%	ON	Yes			
EPIVIR HBV TABLET (ORAL)	21.3%	ON	Yes			
LAMIVUDINE HBV TABLET (ORAL)	0.0%	NR	No-Generic			
BARACLUDE SOLUTION (ORAL)	2.7%	ON	Yes			
HEPSERA (ORAL)	4.7%	ON	Yes			
TYZEKA (ORAL)	0.0%	ON	Yes			
BARACLUDE TABLET (ORAL)	71.3%	ON	Yes			
ADEFOVIR DIPIVOXIL (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - All members were in favor of the motion
 - Motion passes

HEPATITIS C AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PEG-INTRON REDIPEN (SUBCUTANE.)	10.8%	ON	Yes			
PEG-INTRON (SUBCUTANE.)	1.6%	ON	Yes			
INFERGEN (SUBCUTANE.)	0.0%	OFF	No			
PEGASYS VIAL (SUBCUTANE.)	2.2%	ON	Yes			
PEGASYS PROCLICK (SUB-Q)	15.7%	ON	Yes			
PEGASYS SYRINGE (SUB-Q)	20.5%	ON	Yes			
VICTRELIS (ORAL)	4.9%	ON	Yes			
INCIVEK (ORAL)	3.2%	ON	Yes			
OLYSIO (ORAL)	0.0%	NR	No			
SOVALDI (ORAL)	0.0%	NR	No			
RIBAVIRIN TABLET (ORAL)	28.6%	ON	Yes-Generic			
RIBAVIRIN CAPSULE (ORAL)	12.4%	ON	Yes-Generic			
RIBASPHERE 400 MG (ORAL)	0.0%	OFF	No			
REBETOL SOLUTION (ORAL)	0.0%	OFF	No			
RIBASPHERE 600 MG (ORAL)	0.0%	OFF	No			
RIBAPAK (ORAL)	0.0%	OFF	No			
RIBAVIRIN DOSE PACK (ORAL)	0.0%	NR	No-Generic			

- Discussion: Kevin Izard stated that the developer of the polio vaccine gave this breakthrough treatment free to the world and, now we are so far away from that. Kevin Izard feels that Sovaldi should be non-preferred to send a message. Ronald Diamond stated that the pricing of Sovaldi should be part of a larger public discussion. The drug company needs to think about the consequences.
- There was discussion among committee members regarding the recently released hepatitis C guidelines. Dr. Wiggins noted that the guidelines released were for treatment protocols and did not address who to treat. Since many Hepatitis C patients are quite stable, the specifics about when to initiate treatment still need to be addressed in the guidelines. Currently, the state is doing individual clinical review of each PA request.
- Rachel Currans-Henry stated that criteria is still being considered and will be developed, and the state is monitoring what is happening on a national level. We published a provider update with interim Sovaldi PA criteria and have approved Sovaldi for some members.
- Alicia Walker commented that cost is an issue, but we also need to look at associated costs, with not having treatment, and the member not being cured. Dr. Wiggins stated that research in California suggests that overall medical costs are not reduced by treating with Sovaldi.
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ronald Diamond
 - All members were in favor of the motion
 - Motion passes

HIV / AIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VIRAMUNE SUSPENSION (ORAL)	0.1%	ON	Yes			
ZIDOVUDINE TABLET (ORAL)	0.1%	ON	Yes-Generic			
NEVIRAPINE TABLET (ORAL)	0.2%	ON	Yes-Generic			
NORVIR SOLUTION (ORAL)	0.1%	ON	Yes			
NORVIR CAPSULE (ORAL)	1.7%	ON	Yes			
NORVIR TABLET (ORAL)	16.8%	ON	Yes			
EPVIR SOLUTION (ORAL)	0.2%	ON	Yes			
STAVUDINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
ZIDOVUDINE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
VIDEX SOLUTION (ORAL)	0.0%	ON	Yes			
EMTRIVA SOLUTION (ORAL)	0.0%	ON	Yes			
ZIAGEN SOLUTION (ORAL)	0.3%	ON	Yes			
ZIDOVUDINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
EPVIR TABLET (ORAL)	0.6%	ON	Yes			
LEXIVA SUSPENSION (ORAL)	0.0%	ON	Yes			
ZERIT SOLUTION (ORAL)	0.0%	ON	Yes			
VIRAMUNE TABLET (ORAL)	0.4%	ON	Yes			
RESCRIPTOR (ORAL)	0.0%	OFF	No			
SUSTIVA CAPSULE (ORAL)	0.0%	ON	Yes			
LAMIVUDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
DIDANOSINE CAPSULE DR (ORAL)	0.0%	OFF	No-Generic			
EMTRIVA CAPSULE (ORAL)	0.2%	ON	Yes			
ZIAGEN TABLET (ORAL)	0.9%	ON	Yes			
CRIXIVAN (ORAL)	0.0%	ON	Yes			
VIREAD (ORAL)	3.9%	ON	Yes			
STAVUDINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
NEVIRAPINE ORAL SUSP (ORAL)	0.0%	ON	Yes-Generic			
SUSTIVA TABLET (ORAL)	0.5%	ON	Yes			
INVIRASE CAPSULE (ORAL)	0.0%	ON	Yes			
ABACAVIR (ORAL)	0.0%	OFF	No-Generic			
INVIRASE TABLET (ORAL)	0.0%	ON	Yes			
VIRAMUNE XR (ORAL)	0.7%	ON	Yes			
COMBIVIR (ORAL)	1.0%	ON	Yes			
KALETRA SOLUTION (ORAL)	0.2%	ON	Yes			
ISENTRESS TAB CHEW (ORAL)	0.0%	ON	Yes			
EDURANT (ORAL)	0.3%	ON	Yes			
LEXIVA TABLET (ORAL)	0.8%	ON	Yes			
PREZISTA ORAL SUSP (ORAL)	0.0%	ON	Yes			
EPZICOM (ORAL)	3.4%	ON	Yes			
APTIVUS SOLUTION (ORAL)	0.0%	OFF	No			
VIRACEPT (ORAL)	0.2%	OFF	No			
TRUVADA (ORAL)	20.5%	ON	Yes			
LAMIVUDINE-ZIDOVUDINE (ORAL)	0.1%	OFF	No-Generic			
INTELENCE (ORAL)	1.2%	OFF	No			
KALETRA TABLET (ORAL)	1.8%	ON	Yes			
REYATAZ (ORAL)	7.4%	ON	Yes			
ISENTRESS (ORAL)	6.6%	ON	Yes			
APTIVUS CAPSULE (ORAL)	0.0%	OFF	No			
TRIZIVIR (ORAL)	0.5%	ON	Yes			
PREZISTA (ORAL)	11.4%	ON	Yes			
TIVICAY (ORAL)	0.9%	NR	No			
SELZENTRY (ORAL)	0.5%	OFF	No			
ATRIPLA (ORAL)	9.9%	ON	Yes			
ABACAVIR/LAMIVUDINE/ZIDOVUDINE (ORAL)	0.0%	NR	No-Generic			
COMPLERA (ORAL)	3.9%	ON	Yes			
FUZEON (SUB-Q)	0.0%	OFF	No			
STRIBILD (ORAL)	2.1%	OFF	No			

- Discussion: Catherine Decker and Pat Towers wanted to verify the state would be working on a Stribild PA process. Lynn Radmer confirmed that the state is working on a separate PA form for Stribild and procedures to facilitate efficient PA processing.
- Kevin Izard expressed concern about expensive medications like Stribild. One script of expensive medications like this can wipeout other cost savings.
- William Raduege made a motion to accept staff recommendations as presented.

- o Second-Ward Brown
- o All members were in favor of the motion
- o Motion passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EXTAVIA KIT (SUBCUTANE.)	0.0%	OFF	Yes			
EXTAVIA VIAL (SUBCUTANE.)	0.0%	OFF	Yes			
COPAXONE SYRINGE KIT (SUBCUTANE.)	36.5%	ON	Yes			
BETASERON KIT (SUBCUTANE.)	7.8%	ON	Yes			
AVONEX PEN (INTRAMUSC)	10.1%	ON	Yes			
AVONEX (INTRAMUSC.)	7.7%	ON	Yes			
REBIF (SUBCUTANE.)	16.5%	ON	Yes			
REBIF REBIDOSE PEN INJCTR (SUBCUTANE.)	0.1%	ON	Yes			
AMPYRA (ORAL)	5.4%	OFF	No			
AUBAGIO (ORAL)	2.1%	OFF	No			
GILENYA (ORAL)	4.9%	OFF	No			
COPAXONE SYRINGE (SUBCUTANE.)	0.0%	NR	No			
TECFIDERA (ORAL)	8.9%	NR	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - o Second-William Raduege
 - o The vote was 11-1 in favor of the motion. Ronald Diamond opposed the motion stating he was uncomfortable with non-preferring Gilenya based on cost.
 - o Motion passes

IRRITABLE BOWEL SYNDROME						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMITIZA (ORAL)	48.2%	ON	Yes			
LOTRONEX (ORAL)	0.7%	NR	No			
LINZESS (ORAL)	51.1%	ON	Yes			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - o Second-William Raduege
 - o All members were in favor of the motion
 - o Motion passes